Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05595408

Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma

Sponsor: RenJi Hospital

View on ClinicalTrials.gov

Summary

In our study, the ultra-deep sequencing of circulating tumor DNA (ctDNA) and urine tumor DNA (utDNA) were performed to assess whether ctDNA and utDNA can be used as predictive biomarkers for the detection of minimal residual disease (MRD) and early diagnosis of UTUC recurrence, and explored the role of ctDNA and utDNA detection of MRD in the prediction of adjuvant therapy efficacy and prognostic evaluation.

Official title: Circulating and Urine Tumor DNA Dynamics Predict Minimal Residual Disease and Recurrence Risk in Locally Advanced Upper Tract Urothelial Carcinoma(CURATE-UTUC): A Multicenter Prospective Longitudinal Cohort Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

84

Start Date

2022-02-01

Completion Date

2026-12-31

Last Updated

2025-12-09

Healthy Volunteers

No

Interventions

DRUG

Adjuvant chemotherapy

cisplatin/carboplatin-gemcitabine 4-6 cycles

DRUG

adjuvant immunotherapy

immunotherapy for one year

Locations (1)

Renji Hospital

Shanghai, Shanghai Municipality, China